Anders Dahl Johannsen

Aarhus University Hospital

Anders Dahl Johannsen's research has significantly advanced our understanding of COVID-19 vaccination responses in patients with rheumatic diseases. Studies have shown that rituximab-treated rheumatic patients exhibit high seroconversion rates after COVID-19 boost or revaccination, reducing self-imposed isolation and shielding behaviors. Additionally, research on the BNT162B2 vaccine has revealed local and systemic reactogenicity in patients with systemic lupus erythematosus and rheumatoid arthritis, as well as impaired antibody responses. The researcher has also published a case report on rhabdomyolysis following electromyostimulation training and investigated the haemodynamic relevance of peri-operative arrhythmia in patients with concomitant Brugada and sick sinus syndrome.